文献速递免疫规划卫生政策与健康促进

建立非洲区域呼吸道病原体疫苗效果监测网络(AFRO-MoVE)

Establishing the African region monitoring vaccine effectiveness (AFRO-MoVE) network for respiratory pathogens.
PubMed 文献 · Vaccine · 2024-12-31

世界卫生组织与合作方于2021年3月启动非洲区域疫苗效果监测网络(AFRO-MoVE),旨在支持和协调非洲地区可比的新冠疫苗效果研究。网络汇聚22个非洲国家55个机构的200余名专家,通过两阶段支持9项研究并建立数据平台,以提供区域疫苗效果合并估计。

要点

  • AFRO-MoVE网络于2021年3月启动,聚焦非洲区域新冠疫苗真实世界效果监测。
  • 网络汇聚22个非洲国家55个机构的200余名专家,开展10次网络研讨会和6次技术培训。
  • 网络分两阶段支持9项研究,包括3项队列研究和6项检测阴性设计研究。

核心结论

  • AFRO-MoVE网络可形成可持续平台,为非洲区域现有和新型呼吸道病原体疫苗及其他疾病疫苗提供证据知情决策数据和及时的效果监测。
  • 进一步发展和巩固网络活动可助力快速应对未来疫情和大流行。

研究设计与样本

  • 世界卫生组织与合作方于2021年3月启动非洲区域疫苗效果监测网络(AFRO-MoVE),旨在促进和支持非洲地区可比的新冠疫苗效果研究。
  • 网络旨在提供科学专业知识和基础设施平台,鼓励采用稳健的相似研究设计以便合并产生区域疫苗效果估计,并建立可持续的医院、机构和专家网络以评估针对大流行和地方性呼吸道病原体的疫苗。

主要发现

  • 网络成立两年内协调了区域疫苗效果研究,提供了采用稳健方法学的技术指导和通用方案。
  • 网络汇聚了代表22个非洲国家和55个机构的200余名专家,通过举办10次网络研讨会和6次技术培训加强了能力。
  • 55个合作机构中,位于13个国家的25个机构合作实施了区域疫苗效果研究。
  • AFRO-MoVE分两阶段支持研究实施,首先针对新冠疫苗接种优先群体,随后针对普通人群。
  • 网络为9项研究提供技术和资金支持,包括3项针对卫生工作者和患合并症成人的队列研究,以及6项评估疫苗对有症状和重症疾病效果的检测阴性设计研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Population-level vaccination with newly developed vaccines to respond to the COVID-19 pandemic created a need to monitor vaccine effectiveness (VE) in the context of emerging SARS-CoV-2 variants and changing epidemiology. WHO and partners launched the African Region Monitoring Vaccine Effectiveness (AFRO-MoVE) Network in March 2021 to assess the performance of COVID-19 vaccines in real-world conditions in Africa. The Network aimed to facilitate and support comparable COVID-19 vaccine effectiveness studies in the African region, to provide a platform of scientific expertise and infrastructure, encourage the use of robust similar study designs to enable pooling to produce regional VE estimates and to build a sustainable network of hospitals, institutions, and experts to evaluate vaccines against pandemic and endemic respiratory pathogens. In the two years since its inception, the network has coordinated VE studies in the region and provided technical guidance and generic protocols employing robust methodologies. It brought together over 200 experts, representing 22 African countries and 55 organisations, and strengthened capacities by hosting ten webinars and six technical workshops. Of the 55 partners organisations, 25 based in 13 countries collaborated on implementing VE studies in the region. AFRO-MoVE supported study implementation in two phases, first targeting COVID-19 vaccination priority groups, then the general population. The network provides technical and financial support to nine studies, including three cohort studies in health workers and adults with comorbidities, and six test-negative design studies evaluating VE against symptomatic and severe disease. A data platform was established for pooled regional estimates. The AFRO-MoVE Network can form a sustainable platform to provide data for evidence informed decisions and timely VE monitoring for existing and new vaccines against respiratory pathogens and other diseases in the African region. Further development and consolidation of the network's activities can enable rapid response to future epidemics and pandemics.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Gurry CE, Mwenda JM, Nardone A, et al. Establishing the African region monitoring vaccine effectiveness (AFRO-MoVE) network for respiratory pathogens. Vaccine. 2024. PMID: 39743459. doi:10.1016/j.vaccine.2024.126616

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。